Company intelligence / Profile preview

Cyon Therapeutics

Vancouver, British Columbia, Canada

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Cyon developed an anti-PCSK9 antibody (LGT-209) licensed from Novartis. Phase 1 trials successfully demonstrated the drug was well-tolerated and effective in lowering cholesterol, a key mechanism expected to prevent and improve outcomes in sepsis patients[2]. The company planned to move into Phase 2 clinical trials recruiting patients early in disease to reduce sepsis-related morbidity and mortality[2].

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Novartis

Beyond the preview

Go deeper on Cyon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyon Therapeutics.

Explore the full profile